The Ontario Blood Pressure (ON-BP) survey is a communitybased, cross-sectional study using direct observations performed in 2006 to assess the current prevalence of hypertension and its management in the province of Ontario, Canada. In this survey, prevalence of hypertension increased from 3% in the age group of 20-39 years to 52% in the age group of 60-79 years, fairly similar to the 1992 Canadian Heart Health Survey. However, a marked improvement in the management of hypertension is apparent. At the time of the 1992 Canadian Heart Health Survey only 33% of hypertensives were treated and only 13% had their BP controlled to <140/90 mm Hg by drug therapy. 1 In contrast, the ON-BP reports a treatment rate of 82% and a control rate of 66%. 2 Consistent with these marked improvements, recent studies examining administrative databases in Ontario over the period [1994][1995][1996][1997][1998][1999][2000][2001][2002] showed marked increases in the number of prescriptions for antihypertensive drugs and the use of multiple antihypertensive medications. 3, 4 Similar increases in use of antihypertensive drugs were noted in longitudinal national surveys. 5, 6 None of these studies actually measured BP and could not relate drug class utilization to extent of BP control.
The Ontario Blood Pressure (ON-BP) survey is a communitybased, cross-sectional study using direct observations performed in 2006 to assess the current prevalence of hypertension and its management in the province of Ontario, Canada. In this survey, prevalence of hypertension increased from 3% in the age group of 20-39 years to 52% in the age group of 60-79 years, fairly similar to the 1992 Canadian Heart Health Survey. However, a marked improvement in the management of hypertension is apparent. At the time of the 1992 Canadian Heart Health Survey only 33% of hypertensives were treated and only 13% had their BP controlled to <140/90 mm Hg by drug therapy. 1 In contrast, the ON-BP reports a treatment rate of 82% and a control rate of 66%. 2 Consistent with these marked improvements, recent studies examining administrative databases in Ontario over the period [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] showed marked increases in the number of prescriptions for antihypertensive drugs and the use of multiple antihypertensive medications. 3, 4 Similar increases in use of antihypertensive drugs were noted in longitudinal national surveys. 5, 6 None of these studies actually measured BP and could not relate drug class utilization to extent of BP control.
The Canadian Hypertension Educational Program was initiated in 1999 and includes annually updated evidenced-based recommendations for the management of hypertension. At the time of the ON-BP survey the Canadian Hypertension Educational Program guidelines recommended all major drug classes except α-blockers, as first-line agents, and as combination therapy thiazide diuretics with an angiotensin-converting enzyme inhibitor (ACE), AT 1 -receptor blocker (ARB), calcium channel blocker (CCB), or β-blocker (BB). 7 From a public health perspective it is essential to understand to what extent such guidelines are actually being followed and particularly how different drug classes affect treatment and control rates.
To date there has not been a community-based survey of the magnitude of ON-BP in Canada examining the utilization patterns of different classes of antihypertensive medications and their impact on BP control. This study had the following objectives: (i) extent of monotherapy vs. 2+ drug therapy in relation to control rates; (ii) utilization of specific drug classes as monotherapy or in combination and their impact on BP control;
Background
The Ontario Blood Pressure (ON-BP) survey reported high treatment and control rates for hypertension in the province of Ontario, Canada, in a survey performed in 2006. This study examined patterns of utilization of antihypertensive drug classes and their impact on blood pressure (BP) control.
Methods
Cross-sectional, population-based survey of adults, 20-79 years of age (population 7,996,653). Responses are weighted to the Ontario hypertensive population of 1,498,045.
results
Of all hypertensives, 51 and 49% were on monotherapy vs. 2+ drug therapy with similar control rates (86 vs. 80%, respectively). In those on monotherapy a renin-angiotensin system (RAS) blocker was the most commonly used drug class (62%) and use of other drug classes was only ~10%. In those on 2+ therapy, a RAS blocker was also the most common class (80%), followed by a diuretic (67%). In diabetics with hypertension 46 and 54% were on monotherapy vs. 2+ drug therapy with significantly higher control rates on monotherapy (90 vs. 46%). RAS blocker was also the most common drug class (85 and 80%, respectively), but in those on 2+ drugs only 45% were on a diuretic. Control rates did not differ by type of drug treatment in the overall hypertensive population and those with a comorbidity, but were low in diabetics on 2+ therapy and particularly in those on a calcium channel blocker (CCB) or diuretic. articles Antihypertensive Medication and Blood Pressure Control and (iii) patterns of drug use by age, sex, diabetes, and major comorbidities.
Methods
The ON-BP survey was conducted from March to October 2006 and selected a random and representative sample of the adult population (20-79 years of age) in the Province of Ontario. The aim was to recruit 2,500 respondents of Caucasian, Black, EastAsian, and South-Asian ethnic background. Specific details regarding the survey sampling design and methodology have been recently described elsewhere. 2 Estimation weights were used to obtain representative estimates of population parameters. Each responding adult carried one estimation weight representing a number of other "similar" adults in the region of interest. The sum of the estimation weights corresponds to the adult population of Ontario.
Survey participants received a detailed in-home interview, followed by BP measurements and anthropometric data collected at a clinic visit. During the home interview, participants were asked, "Are you taking any treatment(s) for BP?" For respondents who answered "medication, " the interviewer recorded the exact product name from the medication container label. If the medication was not available at the time of the interview, the participant was asked to bring the medication(s) to the clinic where the names were recorded by the registered nurse. If containers were unavailable, the participant verbally reported the names. Medications were classified as BB, CCB, ACE, ARB, or other antihypertensive agents (direct vasodilators and sympaticolytics). Combination pills were allocated to each of the two classes. Persons who used only one active ingredient were defined as receiving monotherapy, and those using >1 as 2+ therapy.
BP was measured in all participants at the clinic visit using the BpTRU device (BpTRU Medical Devices, Coquitlam, British Columbia, Canada) according to the Canadian Hypertension Educational Program guidelines. The validation of this device was performed by Wright et al. 8 An initial reading was obtained with the observer (the nurse) present to verify that the device was functioning properly. Thereafter, the patient was left alone in the examination room, and five additional readings were taken at 1-min intervals. The mean of these five readings was recorded. When the BP was being measured, the patient was seated comfortably with the BP cuff at heart level, and readings were recorded without conversation. The appropriate cuff size was used, and all BP measurements were obtained from the same arm. In addition, for every 10th participant, BP was also measured using a mercury sphygmomanometer (W.A. Baum, Copiague, NY); the order that the devices were used was alternated between participants. The BpTRU measurements were adjusted using a linear regression equation derived from the subsample of participants who had both mercury and BpTRU BP readings. 9 All further references to BP represent the adjusted BpTRU values derived from the following equations: adjusted systolic BP = 11.4 + (0.93 × BpTRU systolic BP) and adjusted diastolic BP = 15.6 + (0.83 × BpTRU diastolic BP). Hypertension is defined as a mean systolic BP ≥140 mm Hg or a mean diastolic BP ≥90 mm Hg or current antihypertensive drug therapy, similar to the definition used by National Health and Nutrition Examination Survey (NHANES). 10 Of the 2,992 participants who agreed to participate, 2,551 had their BP measured, and 733 were hypertensive according to the above criteria.
Use of cholesterol-lowering medication, nonsteroidal antiinflammatory drugs, presence of diabetes and of major comorbidities such as stroke, myocardial infarction, heart failure, and kidney disease were assessed by questionnaire. Diabetes associated with pregnancy was excluded. Hypertensives who had none of the above were categorized as uncomplicated hypertensives.
Sampling errors were estimated for all estimates computed for this survey. Given the complexity of the sampling plan and of the adjustments to the estimation weights, sampling errors were estimated using a replication method known as "Jackknife. " 11, 12 Replication weights were created using the WesVar 4.2 software (Westat, Rockville, MD); the same software was used to create all cross-tables and regression models. The χ 2 analysis was used to test for differences in proportions by age and sex, and by treatment and comorbidities without adjusting for age or sex. Continuous measures are presented as weighted means (and standard errors); t test was used to test for differences in mean age between comorbidities. The coefficient of variation (CV) is calculated as the standard deviation of an estimate divided by its mean. Estimates with coefficient of variation >0.33 or cells with a sample size <10 are considered unreliable 10 and are marked in the tables.
results
The prevalence of hypertension ranged from 17% in those without any comorbidities to 50-60% in those with cardiovascular articles Antihypertensive Medication and Blood Pressure Control disease/diabetes (P < 0.001). Among the hypertensive population, 69% of the hypertensives had uncomplicated hypertension, 17% had diabetes, and another 25% a comorbidity. Overall, 82% of hypertensives were taking antihypertensive drug therapy. Hypertensives with comorbidities were significantly (P < 0.001) more likely to be taking antihypertensive drug therapy compared to those with uncomplicated hypertension (94 vs. 77%). Treatment rates were also very high (99%) in hypertensives taking a cholesterol-lowering medication. In the overall hypertensive population 66% had their BP controlled.
In the 34% of hypertensives with uncontrolled hypertension, the majority (57%) were not receiving antihypertensive medication. Control rates were higher in those with comorbidities or on cholesterol-lowering therapy, but not in those with diabetes ( Table 1) . Use of nonsteroidal anti-inflammatory drugs did not affect control rates; 69% of hypertensives taking nonsteroidal anti-inflammatory drugs were controlled vs. 65% of hypertensives not taking nonsteroidal anti-inflammatory drugs.
In the hypertensives taking antihypertensive drug therapy 51% were on monotherapy, 35% were taking two antihypertensive agents and 14% were taking more than two antihypertensive agents. Control rates were similar in those on monotherapy (86%) vs. those on 2+ drugs (80%). Of those with treated but uncontrolled hypertension, 41% were on monotherapy and 59% are taking 2+ medications. There was only a minor difference in the number of drugs prescribed in controlled (1.6 drugs) and uncontrolled (1.8 drugs) hypertensives. The average age of those taking 2+ medications was significantly (P < 0.05) higher than those taking one antihypertensive agent ( Table 2 ). There was a trend (P = 0.07) for higher prevalence of comorbidities in those taking 2+ antihypertensive agents.
In the hypertensives using antihypertensive medication 71% were using a renin-angiotensin system (RAS) blocker, 39% a diuretic, and 24% a CCB or BB. Those with comorbidities had a higher use of diuretics (52%) and BB (41%); diabetics had a high use of ACE/ARB (82%) and less use of diuretics (25%) ( Table 3 ). In hypertensives using one antihypertensive agent, Table 4) . In hypertensives taking more than one medication, ACE/ARB were also the most commonly (80%) used drug class, closely followed by diuretic (67%), whereas BB and CCB were used by 34-39%. The most common combination was an ACE/ARB plus a diuretic (51%), an ACE/ARB plus a CCB (21%), followed by BB plus a diuretic (9%). The use of other combinations was fairly uncommon (<10%) and had high coefficient of variations. Control rates did not differ by type of drug treatment for the overall hypertensive population and for those with comorbidities ( Table 3) . Breakdown by different monotherapies or 2+ therapies also showed no differences ( Table 4) .
In those using monotherapy, use of ACE/ARB and diuretic did not differ by age, whereas use of BB was significantly less in the older age group and use of CCB tended to be higher (Figure 1) . On the other hand, use of diuretics was markedly higher in females compared to males and use of ACE/ARB significantly lower (Figure 2) . The difference was similar in both age groups, that is, age <60 years and age >60 years (data not shown). Use of BB and CCB did not differ by sex (Figure 2 ). There were no significant differences in use of different drug classes by age or sex in those taking more than one antihypertensive agent (Figures 1 and 2) .
In diabetics with hypertension, 46% were on monotherapy and 54% on 2+ antihypertensive agents. Overall, 90% of hypertensive diabetics using one antihypertensive agent had their BP controlled, but only 46% of those using 2+ antihypertensive agents (Figure 3) . Of the treated and controlled diabetic hypertensives 61% were on monotherapy and 39% on 2+ antihypertensive medication. In those on monotherapy, 85% were using an ACE/ARB and in those on 2+ antihypertensive agents 80%, followed by CCB (60%) and then diuretic (45%). Compared to other groups, in hypertensives with diabetes control rates were low, particularly in those on a diuretic or CCB ( Table 3) articles Antihypertensive Medication and Blood Pressure Control and treatment rates dropped from 97 to 72%. With the lower cutoffs, rates for uncontrolled hypertension significantly increased from 41 to 64%.
discussion
Drug utilization patterns in ON-BP demonstrate that the high treatment and control rates of hypertension in Ontario are associated with high utilization of RAS blockers (i.e., ACE or ARB). Among treated hypertensives, 62% on monotherapy and 80% on 2+ antihypertensive agents are using a RAS blocker. Management of hypertension has dramatically improved in Ontario in recent years. Currently in Ontario, 66% of hypertensives have their BP treated and controlled; only 15% of hypertensives have treated and uncontrolled hypertension and 19% are not treated at all. A cross-sectional survey provides a snapshot of antihypertensive drug use at a given time point, which for many hypertensives does not reflect the first drug prescribed. Initiation with a specific therapy is influenced by guidelines and physician/patient (mis)perceptions, and for ongoing therapy by the impact of antihypertensive effectiveness and side effects as well as the willingness by physician and patient to change/increase therapy with "BP control" as the primary goal. This goal was indeed achieved in a high percentage of hypertensives. Moreover, control rates were very similar for the different classes as monotherapy or as part of 2+ therapy and for the main combinations. This suggests that physicians in Ontario are rather effective in choosing the right drug or drug combinations for BP control in their patients. A cross-sectional survey cannot assess whether the high use of a RAS blocker reflects high initiation of therapy with this group of drugs instead of e.g., a diuretic, or that a large percent was switched to this group of drugs for BP control or side effects to other classes.
Treatment rates were significantly higher in those with one or more risk factors/comorbidities compared to those with uncomplicated hypertension. Not only are individuals with comorbidities more likely to be treated for hypertension, they are also more likely to be taking more than one antihypertensive agent and show higher control rates. In this group, those (52%) on a diuretic had very high (97%) control rates likely reflecting the antihypertensive effectiveness of a diuretic in this older population either alone or combined with a RAS blocker. This group is clearly a high-risk group, and it should not be surprising that physicians would be more aggressive with their therapy. However, other factors may play a role, because recent reports from NHANES also show higher treatment rates in hypertensives with comorbidities but-unexpectedly-similar or lower control rates compared to those with uncomplicated hypertension. 13, 14 Diabetics also showed very high treatment rates but had lower control rates compared to those with uncomplicated hypertension, a pattern similar to NHANES. 13 Control rates were very high (90%) in the 46% on monotherapy but only 46% in those on 2+ drugs. This pattern suggests that uptitration did occur but apparently not sufficiently and/or with less effective drug combinations.
There are significant differences in the utilization pattern of antihypertensive medications in those using monotherapy by age and sex. Hypertensives >60 years of age are significantly less likely to be taking a BB compared to those <60 years of age. Males are significantly more likely to be taking an ACE/ ARB compared to females who are more likely to be taking a diuretic. The lower use of BB in the older population is consistent with current guidelines. 7 The difference in the use of RAS blockers and diuretics was also recently reported by Neutel and Campbell 6 and is clearly not based on guidelines.
The utilization of drug classes also differed in the subgroups with comorbidities or diabetes. As one may expect, use of BBs and diuretics was higher in those with comorbidities. In contrast, use of both was rather low in the group with diabetes. This may reflect concern by physicians about their metabolic effects. However, the low use of diuretics, perhaps too low a dose, very likely contributed to the low control rates (46%) of those requiring more than one drug.
Regarding the number of drugs required to control BP, based on clinical trials, the perception has emerged that "most" hypertensives require multiple antihypertensive drugs. 14, 15 In this survey, nearly half of hypertensives were found to be controlled by one single agent, even in those with diabetes ( Figure 3) . Patients participating in clinical trials usually do not reflect the general population and would not be tried on different single agents. Nonetheless, many do require 2+ agents, particularly patients with diabetes.
Comparing the current Canadian results with those recently published from NHANES, two major differences are apparent. First, effectiveness of therapy is substantially higher in Ontario compared to the United States for the hypertensive population in general and for those with comorbidities in particular. Further analysis needs to be done to identify the potential system barriers and enablers that this difference may be attributable to. Second, use of RAS blockers is two to three fold higher across the different groups of hypertensives compared to the United States. 14 It is tempting to hypothesize that this difference in the uptake of RAS blockers in the United States and Canada contributes to the difference in control rates in clinical practice. Updates from NHANES will be interesting in this regard.
The major strength of this study is the use of direct observations for both drug use and BP by trained interviewers and nurses using a standardized approach. This is a major advantage compared to data collection from administrative databases. Several limitations should be considered. First, as with all surveys of this nature, nonresponse may introduce volunteer bias. However, it is very unlikely that in this particular survey (and not other surveys) hypertensives with treated and controlled BP somehow selectively responded to participate in the survey compared to hypertensives unaware of their BP status or those treated but uncontrolled. To obtain representative estimates of the population, estimation weights were adjusted for age, sex, and ethnicity at the lowest possible geographic level. Another major limitation for this study from ON-BP is the absence of data collection on previous drug use and articles Antihypertensive Medication and Blood Pressure Control on factors determining the choice of antihypertensive agents over time, and in particular for the high use of RAS blockers in Ontario. Third, similar to NHANES, individuals were only included as hypertensive if either their BP was elevated or they stated use of medications for BP. 13 Nonetheless, some drugs, particularly in those on 2+ drugs were likely prescribed for their comorbidities such as congestive heart failure or coronary artery disease.
Perspective for clinical practice: This survey demonstrates that high control rates are achievable in the community not only in those with uncomplicated hypertension but also in those with co-morbidities, and to a less extent in hypertensives with diabetes. The limited use of diuretics as add-on therapy may contribute to the relatively low control rates in diabetics. Individual clinicians would benefit from the use of tools that enable greater vigilance, tracking and monitoring to ensure BP control of their patient population, and particularly of those patients with diabetes.
